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An Enterobacter cloacae isolate was recovered from a rectal swab from a patient hospitalized in France with previous travel to
Switzerland. It was resistant to penicillins, narrow- and broad-spectrum cephalosporins, aztreonam, and carbapenems but re-
mained susceptible to expanded-spectrum cephalosporins. Whereas PCR-based identiﬁcation of the most common carbapen-
emase genes failed, the biochemical Carba NP test II identiﬁed an Ambler class A carbapenemase. Cloning experiments followed
by sequencing identiﬁed a gene encoding a totally novel class A carbapenemase, FRI-1, sharing 51 to 55% amino acid sequence
identity with the closest carbapenemase sequences. However, it shared conserved residues as a source of carbapenemase activity.
Puriﬁed-lactamase FRI-1 hydrolyzed penicillins, aztreonam, and carbapenems but spared expanded-spectrum cephalosporins.
The 50% inhibitory concentrations (IC50s) of clavulanic acid and tazobactam were 10-fold higher than those found for Klebsiella
pneumoniae carbapenemase (KPC), IMI, and SME, leading to lower sensitivity of FRI-1 activity to-lactamase inhibitors. The
blaFRI-1 gene was located on a ca. 110-kb untypeable, transferable, and non-self-conjugative plasmid. A putative LysR family reg-
ulator-encoding gene at the 5= end of the-lactamase gene was identiﬁed, leading to inducible expression of the blaFRI-1 gene.
Carbapenem resistance in Enterobacteriaceae may be related totwo mechanisms: (i) overexpression of a -lactamases pos-
sessing no (or weak) activity against carbapenems (e.g., extended-
spectrum beta-lactamase [ESBL] and cephalosporinases) com-
bined with decreased outer membrane permeability and (ii)
expression of enzymes able to hydrolyze carbapenems, namely,
the carbapenemases (1). The most clinically relevant carbapen-
emases are classiﬁed into three groups according to protein se-
quence identity: (i) the Klebsiella pneumoniae carbapenemase
(KPC)-type enzymes (Ambler class A), ﬁrst described in the
United States but now found worldwide (2, 3); (ii) the VIM, IMP,
and NDM metallo--lactamases (Ambler class B) (1, 4); and (iii)
the OXA-48-type enzymes (Ambler class D), widespread among
Mediterranean countries and progressively disseminating to other
geographical areas (5).
Ambler class A carbapenemases hydrolyze a large variety of
-lactams, including penicillins, cephalosporins, carbapenems,
and aztreonam (6). Their hydrolytic activity is in vitro inhibited by
clavulanic acid and tazobactam. Four main types of class A car-
bapenemases are known:NmcA/IMI, SME,KPC, and several vari-
ants of the GES type (GES-2, -4, -5, -6, and -11) (7).
The SME family includes three variants (SME-1 to -3). These
enzymes have all been chromosome encoded in S. marcescens iso-
lates (8–11). The chromosome-encoded NmcA and IMI enzymes
have been detected in rare isolates of Enterobacter spp. (12, 13).
The gene encoding the IMI-2 variant has been identiﬁed sporad-
ically as plasmid located in environmental strains of Enterobacter
spp. (14). The GES-type family includes 27 variants, only a few of
which possess carbapenemase activity (7). All the GES variants
possess the ability to hydrolyze broad-spectrum cephalosporins,
but only some variants (mainly GES-2, GES-4, and GES-5 in En-
terobacteriaceae) possess amino acid substitutions within their ac-
tive sites (positions 104 and 170 according to the Ambler classiﬁ-
cation) that enlarge their spectra of activity against carbapenems
(7, 15). Although still rare, GES enzymes have been identiﬁed
worldwide. The most prevalent Ambler class A carbapenemase is
KPC. This plasmid-encoded enzyme was ﬁrst identiﬁed in 2001 in
the United States (16). Since then, KPC-producing Enterobacteri-
aceae have spread worldwide, mostly due to the clonal dissemina-
tion of KPC-producing K. pneumoniae isolates of sequence type
258 (ST258) (2, 3).While this studywas being completed, another
class A carbapenemase, BKC-1, was identiﬁed from K. pneu-
moniae in Brazil (17).
The aim of this study was to characterize at the genetic and
biochemical levels the molecular mechanisms of resistance to car-
bapenems from an Enterobacter cloacae isolate.
MATERIALS AND METHODS
Bacterial strains and plasmids. The E. cloacae isolate DUB was recovered
from a urine sample from a patient, hospitalized in a suburb of Paris, with
a previous history of travel (without hospitalization) in Switzerland. Iden-
tiﬁcation of the clinical isolate was done by matrix-assisted laser desorp-
tion ionization–time of ﬂight (MALDI-TOF)mass spectrometry (MALDI
Biotyper CA system; Bruker Daltonics, Billerica, MA, USA). Escherichia
coli TOP10 (Invitrogen, Saint-Aubin, France) was used for cloning exper-
iments and azide-resistant E. coli J53 for conjugation assays. The kanamy-
cin-resistant pBK-CMV(Invitrogen, Saint-Aubin, France)was used as the
cloning vector. Bacterial cultures were grown in Trypticase soy (TS) broth
at 37°C for 18 h unless otherwise indicated.
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Susceptibility testing.Antimicrobial susceptibilities were determined
by the disc diffusion technique on Mueller-Hinton agar (Bio-Rad,
Marnes-La-Coquette, France) and interpreted according to the EUCAST
breakpoints as updated in 2015 (http://www.eucast.org). MICs were de-
termined using the Etest technique (bioMérieux, La Balme-Les-Grottes,
France).
Detection of carbapenemase activity. Carbapenemase activity was
analyzed by using two techniques, namely, the biochemical Carba NP
test (18) and UV spectrophotometry, as previously described (19).
Discrimination between Ambler class A, B, and non-A non-B carbap-
enemases was assessed using the Carba NP test II results, as previously
described (20).
Molecular detection of carbapenemase-encoding genes. PCR
screening for the most common class A carbapenemase genes (blaKPC,
blaIMP, blaVIM, blaNDM, blaOXA-48, blaGES, blaSFC-1, and blaIMI/NMC-A) was
done as previously described (21).
Plasmid extraction and conjugation assays. Plasmid DNA of E. clo-
acae DUB was extracted and analyzed using the Kieser method, as de-
scribed previously (22). Recombinant plasmid DNA was prepared using
Qiagen maxi columns (Qiagen, Courtaboeuf, France). Transfer of the
imipenem resistance marker into E. coli TOP10 was attempted by electro-
poration. Transformants were selected on ticarcillin (100 g/ml)-con-
taining TS agar plates (Oxoid, Dardilly, France). Transfer of the -lactam
resistance marker into azide-resistant E. coli J53 was also attempted by
liquid mating-out assays at 37°C. Transformants were selected on
azide (100 g/ml)- and ticarcillin (100 g/ml)-containing TS agar
plates. Plasmid typing was performed on electrotransformant strains
by using the PCR-based replicon-typing (PBRT) method, as described
previously (23).
Cloning experiments, recombinant plasmid analysis, and DNA se-
quencing. PCR ampliﬁcation of the identiﬁed blaFRI-1 gene was per-
formed by using the internal primers FRI-1A (5=-TGAACTCATTCGCC
TCTCAG-3=) and FRI-1B (5=-CTGCTTCGTCATGTTTGTCG-3=).
Whole-cell DNA of the E. cloacae isolate was extracted using a QIAamp
DNA minikit (Qiagen, Courtaboeuf, France). Partially Sau3AI-restricted
DNA was ligated into the BamHI-restricted pBK-CMV plasmid and in-
troduced into E. coli TOP10 by electroporation. Recombinant plasmids
were selected on ticarcillin (100g/ml)- and kanamycin (50g/ml)-con-
taining Trypticase soy agar plates. The recombinant plasmid possessing
the shortest insert, namely, pFRI, was retained for further analysis. Both
strands of the cloned DNA inserts of recombinant plasmids were se-
quenced by using an Applied Biosystems sequencer (ABI 377). The nucle-
otide and deduced protein sequences were analyzed with software avail-
TABLE 1 MICs of -lactams for E. cloacae DUB, E. coli TOP10 transformed with the natural blaFRI-1-bearing plasmid (pDUB), E. coli TOP10
harboring a recombinant plasmid (pFRI), and the E. coli TOP10 reference strain
-Lactam(s)
MIC (g/ml)
E. cloacae DUB E. coli TOP10(pDUB)a E. coli TOP10(pFRI)b E. coli TOP10
Amoxicillin 256 128 256 2
Amoxicillin CLAc 256 64 96 2
Ticarcillin 256 256 256 2
Ticarcillin CLA 256 96 96 2
Piperacillin 128 12 24 1
Piperacillin TZBd 96 8 12 1
Cefalotin 256 256 256 4
Cefoxitin 256 2 2 2
Ceftazidime 4 2 2 0.12
Ceftazidime CLA 0.78 0.5 0.75 0.12
Ceftazidime TZB 4 1.5 1.5 0.12
Cefotaxime 1 0.38 0.5 0.06
Cefotaxime CLA 0.5 0.12 0.19 0.06
Cefotaxime TZB 1 0.09 0.5 0.06
Cefepime 0.5 0.19 0.19 0.02
Cefepime CLA 0.06 0.06 0.06 0.02
Cefepime TZB 0.25 0.06 0.06 0.02
Cefpirome 1.5 0.25 0.38 0.02
Cefpirome CLA 1 0.06 0.09 0.02
Cefpirome TZB 0.75 0.06 0.38 0.02
Aztreonam 256 256 256 0.09
Aztreonam CLA 256 8 32 0.09
Aztreonam TZB 256 64 256 0.09
Imipenem 8 0.75 4 0.06
Imipenem CLA 4 0.38 2 0.06
Imipenem TZB 4 0.5 1.5 0.06
Meropenem 3 0.12 0.38 0.02
Meropenem CLA 2 0.03 0.12 0.02
MeropenemTZB 4 0.09 0.25 0.02
Ertapenem 24 0.12 0.75 0.06
Ertapenem CLA 8 0.03 0.12 0.06
Ertapenem TZB 4 0.06 0.38 0.06
a pDUB, natural plasmid carrying the blaFRI-1 gene.
b pFRI, the blaFRI-1 gene cloned in the pBK-CMV plasmid.
c CLA, clavulanic acid at a ﬁxed concentration of 4 g/ml.
d TZB, tazobactam at a ﬁxed concentration of 4 g/ml.
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able on the Internet from the National Center for Biotechnology
Information website (http://www.ncbi.nlm.nih.gov/BLAST/).
Protein analysis. -Lactamase extracts from cultures of E. cloacae
DUB and the E. coli TOP10 strain harboring the recombinant plasmid
pFRI were subjected to analytical isoelectric focusing (IEF) analysis. Mul-
tiple nucleotide and protein sequence alignments were carried out online
using the program ClustalW (http://www.ebi.ac.uk/Tools/clustalW2
/index.html).
-Lactamase puriﬁcation. Puriﬁcation of the -lactamase FRI-1 was
carried out by ion-exchange chromatography. E. coli TOP10(pFRI) was
grown overnight at 37°C in 2 liters of TS broth containing ticarcillin (100
g/ml) and kanamycin (50 g/ml). The bacterial suspension was resus-
pended and disrupted by sonication in 10 ml of 20 mM triethanolamine
buffer (pH 7.2) (Sigma-Aldrich, Saint Quentin Fallavier, France) and
cleared by ultracentrifugation. The protein extracts obtained were loaded
onto a preequilibrated S-Sepharose column (Amersham Pharmacia
Biotech) in the same buffer. The -lactamase recovered in the ﬂow-
through was subsequently dialyzed against triethanolamine buffer (pH
9.5), loaded onto a Q-Sepharose column preequilibrated with the same
buffer, and eluted with a linear NaCl gradient (0 to 500 mM). The frac-
tions containing the highest -lactamase activity, as determined qualita-
tively using nitroceﬁn hydrolysis (Oxoid, Dardilly, France), were pooled
and dialyzed overnight against 50 mM sodium phosphate buffer (pH 7).
The protein content was measured by the Bio-Rad DC protein assay. The
protein puriﬁcation rate and the relative molecular mass of the FRI-1
-lactamase were estimated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) analysis.
Kinetic studies.Kineticmeasurements (kcat andKm) of puriﬁed-lac-
tamase FRI-1 were performed as described previously (24). The 50% in-
hibitory concentration (IC50) for FRI-1 was determined as the concentra-
tion of clavulanate or tazobactam that reduced the hydrolysis rate of 100
M benzylpenicillin by 50% under conditions in which FRI-1 was prein-
cubated with various concentrations of inhibitor for 3 min at 30°C before
the substrate was added.
Nucleotide sequence accession number. The nucleotide sequence
data reported in this paper have been submitted to the GenBank nucleo-
tide database under accession no. KT192551.
RESULTS
Susceptibility testing, carbapenemase detection, and IEF analy-
sis. E. cloacae DUB was resistant to amino-, carboxy-, and ureido-
penicillins; narrow-spectrum cephalosporins; aztreonam; and
carbapenems (Table 1). It remained susceptible to broad-spec-
trum cephalosporins (cefotaxime, cefepime, and cefpirome), ex-
cept for ceftazidime (MIC, 4 g/ml). E. cloacae DUB was suscep-
tible to non--lactam antibiotics, except for rifampin. Addition of
tazobactam or clavulanic acid partially restored susceptibility to
FIG 1 Comparison of the amino acid sequence of FRI-1 with those of IMI-1, NMC-A, SME-1, KPC-2, and SFC-1. Dashes indicate the gaps that were inserted
to optimize the alignment, and dashes indicate residues identical to those of BIC-1. The numbering is according to the method described by Ambler et al (33).
The conserved domains of class A-lactamases are in boldface. The residues shaded in gray are conserved among class A carbapenemases. The conserved residues
are marked by asterisks. The arrow indicates the cleavage site for the leader peptide of FRI-1.
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ceftazidime and carbapenems (Table 1). The positivity of the
Carba NP test identiﬁed the expression of carbapenemase. PCR
experiments carried out on puriﬁed DNA of whole-cell E. cloacae
DUB with primers speciﬁc for the most common carbapenemase
genes (blaKPC, blaIMP, blaVIM, blaNDM, and blaOXA-48) remained
negative. The Carba NP test II was therefore performed to identify
the type of carbapenemase. The inhibition of carbapenemase ac-
tivity by tazobactam suggested that this carbapenemase belonged
to the Ambler class A group. Accordingly, additional PCR exper-
iments were performed using primers speciﬁc for rarer Ambler
class A carbapenemase genes (blaGES, blaSFC-1, and blaIMI/NMC-A),
but they also remained negative. IEF analysis revealed that
strain DUB produced an acquired -lactamase with a pI value
of ca. 8.4.
Cloning, conjugation, and transformation of the -lacta-
mase gene. Shotgun cloning resulted in the selection of an E. coli
TOP10(pFRI) recombinant strain that expressed a clavulanic ac-
id-inhibited carbapenemase phenotypewith resistance or reduced
susceptibility to penicillins, ceftazidime, aztreonam, and carbap-
enems. The addition of clavulanic acid partially restored the activ-
ities of the -lactams (Table 1). IEF analysis showed that E. coli
TOP10(pFRI) produced a-lactamasewith a pI value of 8.4, iden-
tical to that identiﬁed in E. cloacae DUB (data not shown). Anal-
ysis of the plasmid DNA extract of the E. cloacae DUB isolate
revealed a ca. 110-kb plasmid. Transfer of the imipenem resistance
marker into E. coli TOP10 by electroporation was successful. In
contrast, mating-out assays failed to give any transconjugant.
PBRT analysis performed using a DNA extract of an E. coli TOP10
transformant (pDUB) (23) failed to identify a plasmid of any
known incompatibility group.
Identiﬁcation of -lactamase FRI-1. DNA sequence analysis
of the 2,863-bp insert of pFRI revealed an open reading frame
(ORF) of 885 bp encoding a 295-amino-acid preprotein, FRI-1
(French imipenemase), with a relative molecular mass of 32.5
kDa. The GC content of this ORF was 39%. The signal peptide
cleavage site was identiﬁed between the alanine and serine resi-
dues at positions 23 and 24 (AS-QV) of FRI-1 (Fig. 1). The -lac-
tamase FRI-1 contained four conserved motifs of class A serine
-lactamases, namely, 70SSFK73, 130SDN132, 166EXXXN170, and
234KTG236 (25) (Fig. 1). Interestingly, FRI-1 contains the amino
acid residues that, associated, have been identiﬁed as a source of
carbapenemase activity in class A -lactamases; 69C, 105H, 167L,
237S, 238C, and 241Y (25–27). The -lactamase FRI-1 shares 55%,
54%, 53%, 53%, and 51% amino acid identity with the class A
carbapenemases NMC-A, IMI-1, SME-1, SFC-1, and KPC-2,
respectively (Fig. 1). It shares 42% amino acid identity with the
recently identiﬁed -lactamase BKC-1 (data not shown). A
dendrogram was generated from the amino acid sequence
alignment of FRI-1 with main class A -lactamases. It showed
that FRI-1 is more closely related to the subgroup that includes
SME-1, IMI-1, and NMC-A than to that of KPC-2, SFC-1, and
BIC-1 (Fig. 2).
Biochemical features of -lactamase FRI-1. The puriﬁcation
state of FRI-1 was estimated to be 95% by SDS-PAGE analysis
(data not shown). Kinetic parameters of the puriﬁed -lactamase
FRI-1 showed that it possessed quite signiﬁcant carbapenemase
activity (Table 2). The highest kcat value for carbapenems was ob-
tained with imipenem and was approximately 39- and 12-fold
higher than those for meropenem and ertapenem, respectively
(Table 2). The kcat/Km values obtained for FRI-1 were close to
those obtained for NMC-A and IMI-1 (Table 2). Notably, the kcat
value for aztreonamwas very high (Table 2), which correlates with
the highMIC values obtainedwith theE. coliTOP10 transformant
and the E. coli TOP10(pFRI) recombinant strain (Table 1). Inhi-
bition studies, as measured by IC50s, showed that the activity of
FRI was weakly inhibited by clavulanic acid (IC50, 90 M) and
tazobactam (IC50, 15 M). These values are in the same range as
those found for SFC-1, 72.8 and 6.9 M for clavulanic acid and
tazobactam, respectively (28, 29). In addition, we observed that
blaFRI-1 expressionwas inducible (8- to 10-fold) by imipenem (5
g/ml) or by cefoxitin (50 g/ml and 200 g/ml).
Genetic environment of the blaFRI-1 gene.Part of the 5,750-bp
insert of the recombinant plasmid pFRI was sequenced to identify
the ﬂanking sequences of the blaFRI-1 gene (Fig. 3). The blaFRI-1
gene was bracketed by two insertion sequences (IS). The closest
IS shared 93% identity with ISRaq1 (GenBank accession no.
AY528232), identiﬁed in Rahnella aquatilis. This ISRaq1-like IS
was truncated by the insertion of another IS belonging to the IS66
family, sharing 87% identity with ISKpn24 (GenBank accession
no. NC_014312). Upstream of blaFRI-1, a gene encoding FRI-R, a
LysR transcriptional regulator sharing 63% amino acid identity
with SmeR, the regulator of SME-1, was identiﬁed. The friR gene
possessed a GC content similar to that of the blaFRI-1 gene
(39%).
DISCUSSION
Our study identiﬁed a novel plasmid-encoded class A carbapen-
emase from the urine of a French patient who had traveled in
Switzerland. The-lactamase FRI-1 shares the highest amino acid
identity with the chromosome-encoded Ambler class A carbapen-
FIG 2 Dendrogram obtained for 16 representative class A -lactamases by
neighbor-joining analysis. The alignment used for the tree calculation was
performed with the ClustalW program. Branch lengths are drawn to scale and
are proportional to the number of amino acid changes. The distance along the
vertical axis has no signiﬁcance. The -lactamases (GenBank accession num-
bers) are BIC-1 (GQ260093), SFC-1 (AY354402), KPC-2 (AY034847), SME-1
(Z28968), IMI-1 (U50278), NMC-A (Z21956), BES-1 (AF234999), CTX-M-1
(X92506), GES-1 (AF156486), BEL-1 (DQ089809), LAP-1 (EF026092),
TEM-1 (AY458016), SHV-1 (AF148850), PER-1 (Z21957), and VEB-1
(AF010416).
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emases NMC-A from E. cloacae (12) and IMI-1 (13). Biochemical
characterization of FRI-1 showed signiﬁcant hydrolysis of carbap-
enemase, and its protein structure analysis identiﬁed conserved
amino acid residues as a source of its carbapenemase activity. As
observed for other class A -lactamases, such as NMC-A (12),
IMI-1 (13), and SFC-1 (30), FRI-1 confers a high level of resis-
tance to aztreonam but does not confer signiﬁcant resistance to
broad-spectrum cephalosporins, such as ceftazidime, cefotaxime,
and cefepime (Table 1). Therefore, its resistance proﬁle differs
from that of KPCs that hydrolyze all extended-spectrum -lac-
tams.
Analysis of the immediate upstream genetic environment of
the blaFRI-1 gene identiﬁed a LysR-type transcriptional regulator,
FriR, as previously observed for other class A carbapenemases,
such as NMC-A, IMI-1, and SME (13, 31, 32). Notably, the GC
content of the blaFRI-1 gene and its regulator friR (39%) differed
from that of E. cloacae genes (ca. 55%), suggesting the acquisition
of the friR-blaFRI-1 locus through a horizontal gene transfer pro-
cess. These results further emphasize that acquisition of carbap-
enemase genes by a group of Enterobacteriaceae results from ac-
quisition “in block” of the-lactamase gene and its regulator from
a nonenterobacterial species acting as the reservoir. The presence
of IS upstreamanddownstreamof theDNA fragment friR-blaFRI-1
suggested that those elements might have been involved in the
mobilization process. The plasmid location of the blaFRI-1 gene
identiﬁed in an enterobacterial species adds to the list of carbap-
enemase genes able to disseminate worldwide.
Finally, this work highlights the need to use, not only molecular-
based techniques, but also biochemical methods for the screening
TABLE 2 Steady-state kinetic parameters of the -lactamase FRI-1 and comparison of parameters obtained for the -lactamases NMC-A (24), IMI-
1 (13), SME-1 (11), KPC-2 (16), SFC-1 (28), and GES-4 (15)
Parameter -Lactam
Valuea
FRI-1 NMC-A IMI-1 SME-1 KPC-2 SFC-1 GES-4
kcat (s
1) Benzylpenicillin 1,060 260 36 19.3 63 NA 130
Amoxicillin 17,000 816 190 181 NA NA 19
Ticarcillin 120 81 NA NA NA NA NA
Piperacillin 2,600 NA 6.1 NA NA NA NA
Cefotaxime 220 286 3.4 0.98 17 8.3 17
Cefepime 28 NA NA NA 12 NA NA
Ceftazidime   0.01 NA 0.5 2.1 2.5
Aztreonam 8,300 707 51 108 66 162 NA
Imipenem 1,790 1,040 89 104 31 54 7.7
Ertapenem 150 NA NA NA NA NA NA
Meropenem 46 12 10 8.9 3.6 6.5 NA
Km (M) Benzylpenicillin 567 28 64 16.7 30 NA 160
Amoxicillin 5,000 90 780 488 NA NA 62
Ticarcillin 393 152 NA NA NA NA NA
Piperacillin 3,000 NA 13 NA NA NA NA
Cefotaxime 5,000 956 190  100 89 700
Cefepime 3,400 NA NA NA 540 NA NA
Ceftazidime   270  230 52 1,500
Aztreonam 5,000 125 93 259 420 484 
Imipenem 1,614 92 170 202 90 82 4.7
Ertapenem 98 NA NA NA NA NA NA
Meropenem 70 4.35 26 13.4 13 26 NA
kcat/Km (mM
1/s) Benzylpenicillin 1,870 9,300 560 1,160 2,100 NA 780
Amoxicillin 3,400 9,060 240 370 NA NA 310
Ticarcillin 305 530 NA NA NA NA NA
Piperacillin 867 NA 470 NA NA NA NA
Cefotaxime 44 300 18  170 93 24
Cefepime 8 NA NA NA 22 NA NA
Ceftazidime  52 0.02  2.1 40 1.7
Aztreonam 1,660 5,600 550 420 160 3.5 
Imipenem 1,109 11,000 520 520 340 660 81
Ertapenem 1,531 NA NA NA 280 250 NA
Meropenem 657 2,700 380 660 NA NA NA
a, no detectable hydrolysis; NA, no data available.
FIG 3 Schematic map of the structures surrounding blaFRI-1 identiﬁed in the
E. cloacae DUB isolate. The genes and their corresponding transcriptional
orientations are indicated by horizontal arrows. Sau3AI restriction sites that
allowed cloning in the pBK-CMV plasmid (pFRI) are indicated.
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of carbapenemase-producing strains due to the growing diversity
of carbapenemases.
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